Have a feature idea you'd love to see implemented?
Let us know!
RLAY Relay Therapeutics Inc
Price (delayed)
$6.19
Market cap
$828.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.52
Enterprise value
$743.04M
Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.
Highlights
The EPS has increased by 13% year-on-year and by 4.5% since the previous quarter
The debt has contracted by 8% YoY and by 2.3% from the previous quarter
RLAY's quick ratio is up by 26% year-on-year but it is down by 24% since the previous quarter
The equity has declined by 16% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of RLAY
Market
Valuations
Earnings
Shares outstanding
133.89M
Market cap
$828.78M
Enterprise value
$743.04M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.21
Price to sales (P/S)
23.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.1
Revenue
$35.21M
EBIT
-$322.83M
EBITDA
-$317.33M
Free cash flow
-$283.24M
Per share
Balance sheet
Liquidity
EPS
-$2.52
Free cash flow per share
-$2.13
Book value per share
$5.14
Revenue per share
$0.27
TBVPS
$5.8
Total assets
$772.55M
Total liabilities
$90.81M
Debt
$51.1M
Equity
$681.74M
Working capital
$659.23M
Debt to equity
0.07
Current ratio
15.64
Quick ratio
15.34
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
-901.3%
Gross margin
100%
Net margin
-916.9%
Operating margin
-1,060.5%
Return on assets
-38.4%
Return on equity
-43.7%
Return on invested capital
-45.9%
Return on capital employed
-44.4%
Return on sales
-916.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RLAY stock price
How has the Relay Therapeutics stock price performed over time
Intraday
-1.75%
1 week
-6.78%
1 month
-15.09%
1 year
-1.75%
YTD
-43.78%
QTD
-12.57%
Financial performance
How have Relay Therapeutics's revenue and profit performed over time
Revenue
$35.21M
Gross profit
$35.21M
Operating income
-$373.37M
Net income
-$322.83M
Gross margin
100%
Net margin
-916.9%
The net margin has soared by 97% YoY
Relay Therapeutics's operating margin has soared by 97% YoY
Relay Therapeutics's net income has increased by 6% YoY
Growth
What is Relay Therapeutics's growth rate over time
Valuation
What is Relay Therapeutics stock price valuation
P/E
N/A
P/B
1.21
P/S
23.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.1
The EPS has increased by 13% year-on-year and by 4.5% since the previous quarter
The P/B is 61% lower than the 5-year quarterly average of 3.1 and 19% lower than the last 4 quarters average of 1.5
The equity has declined by 16% year-on-year and by 9% since the previous quarter
The stock's price to sales (P/S) is 37% less than its last 4 quarters average of 37.0
Efficiency
How efficient is Relay Therapeutics business performance
The return on sales has surged by 97% year-on-year
The ROA is down by 19% YoY and by 3.8% QoQ
The company's return on equity fell by 16% YoY and by 2.3% QoQ
The return on invested capital has declined by 13% year-on-year and by 3.4% since the previous quarter
Dividends
What is RLAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RLAY.
Financial health
How did Relay Therapeutics financials performed over time
Relay Therapeutics's total liabilities has decreased by 40% YoY and by 5% from the previous quarter
RLAY's current ratio is up by 27% year-on-year but it is down by 25% since the previous quarter
The debt is 93% less than the equity
The equity has declined by 16% year-on-year and by 9% since the previous quarter
The debt has contracted by 8% YoY and by 2.3% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.